Relevant bibliographies by topics / Immunocheckpoint

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Immunocheckpoint'

Author: Grafiati
Published: 1 April 2023
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Immunocheckpoint.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Immunocheckpoint"

1

Rizzo, Mimma, Matteo Santoni, and Camillo Porta. "Treatment sequencing strategies in metastatic renal cell carcinoma: A critical interpretation of available data." Journal of Onco-Nephrology 4, no. 3 (2020): 153–64. http://dx.doi.org/10.1177/2399369320943609.

Full text
Abstract:
Therapeutic sequencing strategies for metastatic renal cell carcinoma have evolved significantly over time. For about 10 years, vascular endothelial growth factor receptor-targeted therapies and mammalian target of rapamycin inhibitors have been the standard of care. About 5 years ago an immunocheckpoint inhibitor, nivolumab, has opened new therapeutic perspectives. Recent clinical studies have confirmed the biological rationale of combining two immunocheckpoint inhibitors or vascular endothelial growth factor-targeted therapies plus immunocheckpoint inhibitors, demonstrating an improvement in
APA, Harvard, Vancouver, ISO, and other styles
2

Singh, Navdeep, Sandeep Singh Lubana, George Constantinou, and Andrea N. Leaf. "Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma." Case Reports in Oncological Medicine 2020 (May 15, 2020): 1–5. http://dx.doi.org/10.1155/2020/7492634.

Full text
Abstract:
Immunocheckpoint inhibitor (ICI) therapy has provided significant clinical improvements in the treatment of several malignancies. The purpose of this report is to increase awareness of hypereosinophilia associated with checkpoint inhibitors, a topic that has been rarely reported. Hypereosinophilia may need to be addressed especially if eosinophil counts increase to levels where hypereosinophilic visceral complications can occur. We are presenting a case of a 57-year-old male with hypereosinophilia that was seen in the setting of progression of metastatic non-small-cell lung cancer during and a
APA, Harvard, Vancouver, ISO, and other styles
3

Borghaei, Hossein. "Emerging evidence of immunocheckpoint inhibitors in non-small cell lung cancer." Annals of Oncology 28 (October 2017): ix20. http://dx.doi.org/10.1093/annonc/mdx552.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Cazzato, Gerardo, Eliano Cascardi, Anna Colagrande, et al. "T Cell Immunoglobulin and Mucin Domain 3 (TIM-3) in Cutaneous Melanoma: A Narrative Review." Cancers 15, no. 6 (2023): 1697. http://dx.doi.org/10.3390/cancers15061697.

Full text
Abstract:
T cell immunoglobulin and mucin domain 3 (TIM-3) is an inhibitory immunocheckpoint that belongs to the TIM gene family. Monney et al. first discovered it about 20 years ago and linked it to some autoimmune diseases; subsequent studies have revealed that some tumours, including melanoma, have the capacity to produce inhibitory ligands that bind to these receptor checkpoints on tumour-specific immune cells. We conducted a literature search using PubMed, Web of Science (WoS), Scopus, Google Scholar, and Cochrane, searching for the following keywords: “T cell immunoglobulin and mucin-domain contai
APA, Harvard, Vancouver, ISO, and other styles
5

Santoni, Matteo, Daniel Y. C. Heng, Gaetano Aurilio, et al. "Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma." Current Drug Targets 21, no. 4 (2020): 416–23. http://dx.doi.org/10.2174/1389450120666191017113051.

Full text
Abstract:
Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor
APA, Harvard, Vancouver, ISO, and other styles
6

Mejías, Claudia, and Osmany Guirola. "Pharmacophore model of immunocheckpoint protein PD-L1 by cosolvent molecular dynamics simulations." Journal of Molecular Graphics and Modelling 91 (September 2019): 105–11. http://dx.doi.org/10.1016/j.jmgm.2019.06.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ebata, T., T. Shimizu, S. Iizumi, et al. "Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials." Annals of Oncology 28 (November 2017): x40. http://dx.doi.org/10.1093/annonc/mdx658.004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Sonmez, Ozlem, Ozlem Nuray Sever, Basak Oyan, and Osman Gokhan Demir. "Immunotherapy releated cardiomyopathy." Journal of Clinical Oncology 35, no. 15_suppl (2017): e14601-e14601. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e14601.

Full text
Abstract:
e14601 Background: Side effects of immunotherapies also differ from classical cytoxic chemotherapy agents such as effects. Cardiomyopathy is a relatively rare complication. Studies have shown that the risk of developing myocarditis is higher when the ipilimumab / nivolumab combination is used than when the single agent nivolumab is used. ImmunoCheckpoint inhibitors are associated with an increase in immunologic response and immunosuppressives such as corticosteroids, TNF-alpha antagonists and mycophenolate acetate are used in treatment.In this study, we aimed to report cardiac toxicity in pati
APA, Harvard, Vancouver, ISO, and other styles
9

Saigi, Maria, Juan J. Alburquerque-Bejar, and Montse Sanchez-Cespedes. "Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front." Oncogene 38, no. 31 (2019): 5921–32. http://dx.doi.org/10.1038/s41388-019-0855-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Takamori, S., T. Komiya, and E. Powell. "P75.06 Survival Benefit From Immunocheckpoint Inhibitors in Stage IV Non-Small Cell Lung Cancer Patients With Brain Metastases." Journal of Thoracic Oncology 16, no. 3 (2021): S575—S576. http://dx.doi.org/10.1016/j.jtho.2021.01.1040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Immunocheckpoint"

1

SCARABEL, LUCIA. "Predictive and prognostic value of the HLA-G immunocheckpoint in metastatic colorectal cancer treated with FOLFIRI regimen." Doctoral thesis, Università degli Studi di Trieste, 2019. http://hdl.handle.net/11368/2991034.

Full text
Abstract:
In recent years, new and innovative immunotherapy drugs entered the market revolutionizing the clinical management of patients suffering of cancer diseases. These strategies aim to reinforce the immune system through the interaction with immune checkpoint inhibitors including human leukocyte antigen-G (HLA-G), due to its immune suppressive properties. The goal is to better understand the natural history of the cancers, the differential outcome in subgroup of patients, response to cancer treatment, develop of toxicity from chemotherapy treatment, all in relation to polymorphisms in immune genes
APA, Harvard, Vancouver, ISO, and other styles
2

MONTESANO, Luigi. "Analysis of infiltrating γδ T cells in cutaneous melanoma: a hypothetic crosstalk for new immunotherapy". Doctoral thesis, Università degli Studi di Palermo, 2022. https://hdl.handle.net/10447/564105.

Full text
Abstract:
Introduction: Melanoma is one of the most frequently occurring skin cancer and remains an important cause of mortality mainly in Caucasian populations. In clinical practice, the standard treatment for localized melanoma is surgical resection but for metastatic melanoma, few treatments are available, where chemo and radio-therapies are rarely indicated. Immunotherapy has revolutionized the management of metastatic melanoma that, as in others tumors, uses your body's own immune system to help fight cancer. Therapies targeting the immune checkpoint molecules have achieved objective responses i
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Immunocheckpoint"

1

Moerdler, Scott, and Xingxing Zang. PD-1/PDL-1 Inhibitors as Immunotherapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0010.

Full text
Abstract:
Programmed death 1 (PD-1), a member of the B7-CD28 immunoglobulin superfamily, and its ligands PD-L1/PD-L2 inhibit T-cell activation. They also play a key role in the tumor microenvironment, allowing for cancer immune escape. PD-1 is induced on a variety of immune cells, including tumor-infiltrating lymphocytes (TILs), while PD-L1 is found on many types of solid tumors including ovarian cancer and some TILs. The use of immunocheckpoint inhibitors like anti-PD-1 and anti-PD-L1 therapies has been shown to reactivate the immune system to attack tumor cells. Ovarian cancers have been shown to be r
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Immunocheckpoint"

1

Fujimoto, Nobukazu. "Immunocheckpoint Blockade in Malignant Pleural Mesothelioma." In Asbestos-related Diseases. IntechOpen, 2020. http://dx.doi.org/10.5772/intechopen.89116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Matsuda, Asako, and Nobukazu Fujimoto. "Immunotherapy in Malignant Pleural Mesothelioma." In Advances in Precision Medicine Oncology. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.95823.

Full text
Abstract:
Malignant pleural mesothelioma (MPM) is an extremely aggressive plural malignancy mainly caused by asbestos exposure. Basic research about the immune suppressive tumor microenvironment in MPM has suggested that MPM might be a good candidate for immune therapy. Immunocheckpoint inhibitors have shown some promising results. A phase Ib trial with pembrolizumab, an antibody specific for the programmed cell death 1 protein (anti-PD-1), showed efficacy in patients with programmed death-ligand 1 (PD-L1)-positive MPM. Among 25 patients tested, 5 patients (20%) achieved a partial response. A Japanese g
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Immunocheckpoint"

1

Mondello, Patrizia, Matt Teater, Lorena Fontan, et al. "Abstract 797: Targeting HDAC3 reactivates immunosurveillance and enhances immunocheckpoint activity in B-cell lymphoma." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-797.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Liu, Jia, Jia Bo Zheng, Chau Wei Wong, et al. "IDDF2020-ABS-0118 Long non-coding RNA LRTIS regulates MLL1-mediated immunocheckpoint remodelling in esophageal squamous cell carcinoma." In Abstracts of the International Digestive Disease Forum (IDDF), 22–23 November 2020, Hong Kong. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-iddf.3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Immunocheckpoint"

1

Jin, Yuanyang, and Zhimin Suo. Immunocheckpoint inhibitors for advanced gastric cancer or gastroesophageal junction cancer with different microsatellite stability: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.10.0106.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Immunocheckpoint' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography